Replies to post #6696 on Halozyme Therapeutics Inc (HALO)

[biotechinvestor1]

Royalty revenue is different than milestones or upfront payments. The $40 million from VIIV upfront payment does not count toward royalties.

[Fred Kadiddlehopper]

My valuation is base on my rule of thumb of 2% return on earnings per share. It was an accurate working model before the refi fiasco and I think it's still valid in today's interest rate environment except for the list of things we've talked about that are holding the pps back.